Medistem Achieves Important ERC Stem Cell Clinical Trial Milestone MarketWatch (press release) ... Medistem Inc. (pinksheets:MEDS) announced today positive safety data from the first 5 patients enrolled in the Non-Revascularizable IschEmic Cardiomyopathy treated with Retrograde COronary Sinus Venous DElivery of Cell TheRapy (RECOVER-ERC) trial.
No comments:
Post a Comment